Mr. Joshua Bartch reports

MYDECINE INNOVATIONS GROUP ANNOUNCES LISTING ON THE CANADIAN SECURITIES EXCHANGE AND DELISTING FROM THE NEO

Mydecine Innovations Group Inc. has received approval to have the common shares of the company listed on the Canadian Securities Exchange. Consequently, the company has also submitted a request to Neo Exchange Inc., operating as Cboe Canada, to delist the common shares from Neo.

The common shares are expected to be delisted from Neo at the close of business on Oct. 5, 2023, and will begin trading on the CSE under the symbol MYCO at the opening of markets on Oct. 6, 2023. No action is required by shareholders in connection with this change of listing.

Management is excited about the listing of the common shares on the CSE and the opportunities it provides to its investors, as the company continues the ongoing development of its business operations. In addition, the company expects that being listed on a junior stock exchange will help reduce the regulatory compliance costs for the company and allow it to preserve capital while it continues to undertake its growth process and path toward financial self-sustainability.

About Mydecine Innovations Group Inc.

Mydecine is a publicly traded, prerevenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions, such as pain, anxiety, depression, addiction and PTSD (posttraumatic stress disorder), along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a National Institute on Drug Abuse-financed (NIDA) trial at Johns Hopkins University. Mydecine is also developing MYCO-006-short-acting chemical analogs derived from 3,4-methylenedioxy-methamphetamine (MDMA) for treating various conditions, including anxiety and pain. Mydecine utilizes cutting-edge artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them affordable and accessible to the general public upon Health Canada and U.S. Food and Drug Administration (FDA) approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others.

We seek Safe Harbor.